3PBIOVIAN is a leading pan-European biologics CDMO formed in 2024 following the merger of BIOVIAN and 3P Biopharmaceuticals. The company maintains manufacturing sites in Spain, Finland, and offices in the United States to support its end-to-end CDMO offerings, which include mammalian- and microbial-based biologics, viral vectors, cell therapies, and plasmids. 3PBIOVIAN also provides drug substance and drug product services from the preclinical stages of development through commercial manufacturing.